Efmoroctocog alfa

Drug Profile

Efmoroctocog alfa

Alternative Names: Antihaemophilic factor VIII (recombinant), Fc fusion protein; BIIB-031; Efraloctocog alfa; Elocta; Eloctate; Factor VIII-Fc; FVIII-Fc; Long-lasting factor VIII fusion protein; Recombinant factor VIII Fc; Recombinant factor VIII Fc fusion protein; rFVIII-Fc

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum; Syntonix Pharmaceuticals
  • Class Blood coagulation factors; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 10 Jul 2017 Health Canada approved the transfer of the marketing licenses for efmoroctocog alfa to Bioverativ Canada
  • 18 May 2017 Registered for Haemophilia A in Saudi Arabia (IV)
  • 01 Feb 2017 Biogen has separated its Haemophilia Business under a new company Bioverativ
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top